Chronic myeloid leukemia patients imatinib resistance

BCR-ABL Mutations and Imatinib Resistance in Chronic Myeloid Leukemia Patients... 

Frank O, Brors B, Fabarius A et al. Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. Leukemia 2006 20 1400-1407. 

Soverini S, Martinelli G, Amabile M et al. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clin Chem 2004 50 1205-1213. Jaeobberger JW, Sramkoski RM, Frisa PS et al. Immunoreactivity of Stat5 phosphorylated on tyrosine as a eell-based measure of BCR-ABL kinase activity. Cytometry A 2003 54 75-88. 

Shah N, Pasquini R, Rousselot P et al. Dasatinib (SPRYCEL) vs. escalated dose of imatinib (IM) in patients (pts) with ehronie phase chronic myeloid leukemia (CP-CML) resistant to imatinib results of the CA180-017 START-R randomized study (Abstract 167). B/ooii2006 108 53a. 

Imatinib is a protein-tyrosine-kinase inhibitor. Imatinib inhibits proliferation and induces apoptosis in BCR-ABL positive cell lines as well as fresh leukemic cells from Philadelphia chromosome-positive (Ph-r) chronic myeloid leukemia (CML). Imatinib inhibits tumor growth of BCR-ABL transfected murine myeloid cells and BCR-ABL positive leukemia lines derived from CML patients in blast crisis. It also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-Kit, and inhibits PDGF- and SCF-mediated cellular events. It is indicated in the treatment of newly diagnosed adult patients with Ph-t CML in chronic phase patients with Ph-t CML in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha treatment children with Ph-t chronic phase CML whose disease has recurred after stem cell transplant or who are resistant to interferon-alpha therapy and treatment of gastrointestinal stromal tumors (GIST). 

Elias MH, Baba AA, Husin A, Sulong S, Hassan R, Sim GA, Wahid SEA, Ankathil R. HOXA4 gene promoter hypermethylation as an epigenetic mechanism mediating resistance to imatinib mesylate in chronic myeloid leukemia patients. Biomed Res Int 2012 2013 129715. doi 10.1155/2013/129715. 

Cortes J, Guilhot F, Rosti Get al. Dasatinib (SPRYCEL) in patients (pts) with chronic myelogenous leukemia in aeeelerated phase (AP-CML) that is imatinib-resistant (TM-R) or intolerant (IM-I) updated results of the CA180-005 START-A phase 11 study (Abstract 2160). Blood 2006 108 613a. Cortes J, Rousselot R Kim DW et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007 109 3207-3213. 

Cortes J, Rousselot P, Kim DW et al. (2007) Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109 3207-3213... 

Gorre ME, Ellwood-Yen K, Chiosis G et al. (2002) BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 100 3041-3044... 

---